Pharmacological activation of PPARγ in a T cell-transfer colitis model resulted in increased colonic Tregs and decreased Th17 cells in the gut mucosa, whereas deletion of PPARγ in CD4+ T cells impaired mucosal Tregs and enhanced colitogenic Th17 responses in mice with CD4+ T cell-induced colitis [168]. This evidence concerns the gene PPARG and colitis.